Trial Profile
An Escalating, Multiple-Dose Study in Ragweed Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Ragweed.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ragweed SPIRE (Primary)
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Circassia; Niox
- 12 Feb 2010 Interim results reported in a Circassia media release.
- 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.